Showing results (191-200 of 224) with videos related to
Sort By:
Pageof 23
The Cochrane Database of Systematic Reviews|November 30, 2018
Omega-6 fats for the primary and secondary prevention of cardiovascular diseaseLee Hooper, Lena Al-Khudairy, Asmaa S Abdelhamid, et al.The Cochrane Database of Systematic Reviews|July 19, 2018
Omega-6 fats for the primary and secondary prevention of cardiovascular diseaseLee Hooper, Lena Al-Khudairy, Asmaa S Abdelhamid, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 18, 2017
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTRScott H Donaldson, George M Solomon, Pamela L Zeitlin, et al.Journal of Clinical Microbiology|November 12, 2010
Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centersFranziska A Stressmann, Geraint B Rogers, Erich R Klem, et al.JCI Insight|December 20, 2019
Dynamic perfluorinated gas MRI reveals abnormal ventilation despite normal FEV1 in cystic fibrosisJennifer L Goralski, Sang Hun Chung, Tyler M Glass, et al.The Journal of Clinical Investigation|June 4, 2014
Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressureAshley G Henderson, Camille Ehre, Brian Button, et al.Journal of Dental Education|May 10, 2013
Framework for e-learning assessment in dental education: a global model for the futureCarolina R Arevalo, Stephen C Bayne, Josie A Beeley, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 4, 2021
Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-studyScott H Donaldson, Beth L Laube, Peter Mogayzel, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 14, 2024
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC StudyScott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.ERJ Open Research|October 30, 2020
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b studySilke van Koningsbruggen-Rietschel, Jane C Davies, Tacjana Pressler, et al.Pageof 23